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S-Alkyl-N-alkylisothiourea compounds containing various cyclic amines were synthesized in the search
for novel nonimidazole histamine H3 receptor (H3R) antagonists. Among them, four N-alkyl S-[3-(piper-
idin-1-yl)propyl]isothioureas 18, 19, 22, and 23 were found to exhibit potent and selective H3R antago-
nistic activities against in vitro human H3R, but were inactive against in vitro human H4R. Furthermore,
three alkyl homologs 18–20 showed inactivity for histamine release in in vivo rat brain microdialysis,
suggesting differences in antagonist afﬁnities between species. In addition, in silico docking studies of
N-[4-(4-chlorophenyl)butyl]-S-[3-piperidin-1-yl)propyl]isothiourea 19 and a shorter homolog 17 with
human/rat H3Rs revealed that structural differences between the antagonist-docking cavities of rat and
human H3Rs were likely caused by the Ala122/Val122 mutation.
 2013 Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecom-Histamine is an endogenous biogenic amine that has a number
of pathophysiological roles. These include not only those in
peripheral tissues such as in inﬂammatory and allergic reactions
and gastric acid secretion, but also those in the central nervous
system (CNS), which include regulation of the sleep–wake cycle,
cognitive function, feeding and drinking behavior and circadian
rhythms. These histamine-regulated functions are mediated
through four distinct G protein-coupled receptors, referred to his-
tamine H1, H2, H3, and H4 receptors.1 The H3 receptor (H3R),
which is mainly located on the presynaptic membrane of the his-
taminergic neurons in the CNS, is coupled to the Gi/o protein, and
acts by decreasing of the intracellular level of cyclic adenosine
monophosphate (cAMP) by inhibiting adenylylcyclase.2 H3R has
high constitutive and spontaneous activity, and several drugs
that are classically considered as antagonists have been classiﬁed
as either inverse agonists or neutral antagonist.3 Since the ﬁrst li-
gand for H3R was described in 1987,4 a variety of H3R antagonists
such as thioperamide and clobenpropit have been developed
(Fig. 1).5 However, these molecules contain an imidazole ring,
and have been found to additionally inhibit hepatic cytochrome
P450 enzymes, as well as having the potential to inﬂuence the
metabolic pathway of co-administered drugs.6 In addition, owingto the difﬁculties in penetrating the blood–brain barrier, they
may be unsuccessful in acting on their target CNS disorders.2
Hence, it is expected that the development of nonimidazole H3R
antagonists/inverse agonists as potential therapeutic agents will
be extremely useful. Although a small number of such com-
pounds have already reached clinical trials, including BF2.649
(pitolisant),7 CEP-26401,8 and ABT-239,9 they have had little suc-
cess (Fig. 1).10
There is signiﬁcant sequence homology between the human (h)
and rat (r) H3Rs; however, sequence analysis and molecular mod-
eling studies suggested that key amino acids at positions 119 and
122 in transmembrane (TM) region 3 play important roles in ligand
recognition, and these are known to vary between the two
species.11 The pharmacology of H3R ligands has been shown to
species-dependent, with some compounds showing distinct afﬁn-
ity proﬁles. Therefore, the identiﬁcation of novel H3R antagonists/
inverse agonists that are speciﬁc to rats or humans is viewed as
an important issue.12
The H4 receptor (H4R), which is mainly expressed in immune
and inﬂammatory cells of the spleen, thymus, and bone marrow,
as well as in leukocytes,13 is considered as a target for the treat-
ment of chronic allergic and inﬂammatory diseases. H4R has also
been identiﬁed as a Gi/o protein-coupled receptor, and has consti-
tutive activity like H3R.14 The hH4R shares 37.4% sequence identity
at the protein level, and 58% identity in the TM domains with
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Figure 1. Structures of imidazole or nonimidazole H3R antagonists.
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ligands also have a high afﬁnity with H4Rs.16
An extremely potent H3R inverse agonist, clobenpropit is
composed of an imidazole ring, a propyl spacer and an isothiourea
central core that is connected to a lipophilic 4-chlorobenzyl group
(Fig. 1).5,17 During our investigations into novel and potent H3/H4R
ligands,18 we have reported an efﬁcient synthetic method for S-al-N
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Scheme 1. Synthesis of isothiourea 19 and amide 24. Reagents and conditions: (a)
Ph3P, CH3CN, MW, 200 C, 15 min; (b) 4-chlorobenzaldehyde, NaOMe, DMF, MW,
200 C, 15 min; (c) H2/Pd–C, THF–MeOH, 50 min; (d) NH2NH2H2O, EtOH, MW,
120 C, 15 min; (e) PPI, toluene, 60 C, 0.5 h; (f) 1-piperidinepropanol, TMAD, Bu3P,
THF, rt, 16 h; (g) NH2NH2H2O, EtOH, rt, 16 h; (h) ethyl 4-bromobutyrate, MeCN,
reﬂux, 2 h; (i) 6NHCl, reﬂux, 1.5 h; (j) 5, (EtO)2P(O)CN, Et3N, DMF, 14 h.kyl-N-alkylisothioureas.19 In the present paper, using this synthetic
method, we ﬁrst examined whether substitution of the imidazole
of clobenpropit with various cyclic amines affected the potency
and afﬁnity of hH3R. We then evaluated the effect of varying the
length of the alkyl spacer between the isothioureylene and 4-chlo-
rophenyl group. Further, the effects of para-substituents on the
phenyl group, and conversion of the isothiourea central core into
a carbamoyl group were examined. Among the molecules evalu-
ated, novel isothiourea derivative 19 (OUP-186) and related struc-
tures were found to exhibit potent and selective H3R antagonistic
activities, whilst being inactive against hH4R. However, 19 and
its homologs did not have any effect on histamine release when
assessed using in vivo rat brain microdialysis. This discrepancy
between in vitro and in vivo studies prompted us to investigate
the structural differences in the ligand-binding cavities of hH3R
and rH3R using molecular modeling.
We designed the new nonimidazole H3R antagonists by modiﬁ-
cation of clobenpropit, substituting the imidazole with typical
secondary cyclic amines: pyrrolidine, morpholine, piperidine,
methylpiperadine, and piperazine (Scheme 1). The synthesis of
an important intermediate 4-chlorophenylbutyl amine 5,
commenced from commercially available bromopropylphthali-
mide 1. Using microwave (MW) irradiation in the four synthetic
steps, 4-(4-chlorophenyl)butan-1-amine 5 was synthesized in
rapid and straightforward manner through formation of phospho-
nium salt 2 (85%), subsequent Wittig oleﬁnation (65%), catalytic
reduction of alkene 3 (98%), and deprotection of phthalimide 4
with hydrazine (82%). The H3R antagonist target, N-[(4-chloro-
phenyl)butyl]-S-[3-(piperidin-1-yl)propyl]isothiourea 19, was syn-
thesized from amine 5 by using the protocol that we previously
reported for the preparation of S-alkyl-N-alkylisothioureas.19 Reac-
tion of 5with 3-phenylpropionyl isothiocyanate (PPI)19 as an inter-
calating agent of SCN atoms afforded thiourea 6 (46%). This
thiourea 6 was subsequently converted into isothiourea 7 (76%)
via Mitsunobu S-alkylation with 1-piperidinepropanol using
N,N,N0,N0-tetramethylazodicarboxamide (TMAD) and tributylphos-
phine. Selective cleavage of the N–CO bond of 7 with hydrazine
hydrate, with retention of the ﬁssile S-alkyl moieties, produced
target compound 19 (52%),20a which was subsequently treated
with hydrochloric acid to give a dihydrochloride.
In addition, amide compound 24 was easily prepared via three
steps starting from piperidine, as outlined in Scheme 1. The other
S-alkyl-N-alkylisothioureas (10–18 and 20–23) and amide analogs
25 and 26 were successfully synthesized in good yields using the
reaction conditions detailed for 19 and 24, respectively. All ﬁnal
compounds (10–26) were provided as di- or monohydrochlorides,
and their structures were conﬁrmed using standard spectral tech-
niques (1H and 13C NMR, IR, and HRMS).20b
The seventeen synthesized compounds were tested consisting
of an in vitro functional assay using LANCE kit (PerkinElmer) with
ES-392-C and ES-393-C cells that stably express hH3R and hH4R,
respectively (PerkinElmer). All tested compounds showed antago-
nistic activities for hH3R. Potencies (pIC50) were determined by
analyzing concentration–response curves obtained for the test
compounds in the presence of agonist R-a-methylhistamine at
EC80 concentration (see Supplementary data, Section 2). As 3-pip-
eridino- or pyrrolidinopropyl groups were identiﬁed as being the
key pharmacophores in the nonimidazole antagonists that have
reached clinical trials (Fig. 1),10 the spacer between the cyclic
amines and central isothiourea was set as three methylene–car-
bons in the ﬁrst step (Table 1). The respective pIC50 values for pyr-
rolidine and piperidine derivatives 10 and 12 were 7.7 and 7.1
(entries 1 and 3), but those of morpholine, methylpiperazine, and
piperazine derivatives 11, 13, and 14 gave lower values of
5.2–5.8 (entries 2, 4, and 5). Among these compounds, piperidine
analog 12 was previously reported as FUB661 (pA2 = 7.4) by Stark
Table 1
hH3R antagonistic potencies of isothioureas containing various cyclic amines
N (CH2)3 S NH
(CH2)n
NH
ClX
Entry Compd no. Amine n pIC50a,b
1 10 N 1 7.7 ± 0.1
2 11 O N 1 5.8 ± 0.4
3 12(FUB661) N 1 7.1 ± 0.4
4 13 MeN N 1 5.9c
5 14 HN N 1 5.2c
6 15 N 2 7.5 ± 0.1
7 16 O N 2 6.5 ± 0.2
8 17(OUP181) N 2 8.1 ± 0.2
a The pIC50 values represent the mean ± SEM of three independent experiments.
b Reference agonist: (R)-a-methylhistamine.
c The pIC50 values for less active compounds (pIC50 < 7.0) represent results of
single experiments.
Table 2
The inﬂuence of elongation of linker between isothiourea moiety and 4-chlorophenyl
group
N (CH2)3 S NH
(CH2)n
NH
Cl
Entry Compd no. n pIC50a pA2b
1 12 1 7.1 ± 0.4 7.4
2 17 (OUP-181) 2 8.1 ± 0.2 7.4
3 18 3 8.2 ± 0.1 8.7
4 19 (OUP-186) 4 8.2 ± 0.1 9.6
5 20 5 7.5 ± 0.1 8.0
6 Clobenpropit 9.1 ± 0.2 10.0
a The pIC50 is the man value of three independent experiments.
b The pA2 values were estimated by single experiments for only reference
purposes.
Table 3
pIC50 and pA2 data for isothioureas and amides
N (CH2)3 A (CH2)4 R
Entry Compd no. A R pIC50a pA2b,c
1 19 S N
H
NH
Cl
8.2 ± 0.1 9.6
2 21 CF3 7.8 ± 0.3 7.9
3 22 CN 8.7 ± ± 0.1 8.7
4 23 N 8.2 ± 0.0 8.7
5 24 N
H
O
Cl
6.9 n.d.
6 25 CF3 6.9 n.d.
7 26
H
N
O
Cl
6.5 n.d.
a The pIC50 is the mean ± SEM of three independent experiments, while that of
less active compounds (pIC50 < 7) represents results of single experiments.
b The pA2 values were estimated by single experiments for only reference
purposes.
C n.d. = not determined.
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compounds 15–17, which were tethered to the chlorophenyl group
by a C2 chain, gave pIC50 values of 7.5, 6.5, and 8.1, respectively
(entries 6–8). The high pIC50 value achieved for piperidine com-
pound 17 (OUP-181) motivated us to optimize the length of the al-
kyl-spacer to enhance the activity against H3R. In order to acquire
more detailed information on the compounds, the antagonistic
afﬁnities (pA2) were additionally estimated using a negative loga-
rithm of the molar concentration of a competitive antagonist,
which requires a doubling of the concentration of agonist to com-
pensate for the action of the antagonist (Table 2).20a The pIC50 val-
ues for C3- and C4-piperidine homologs 18 and 19 showed a slight
increase (8.2 and 8.2, respectively) on elongation of the carbon
chain, while the pA2 value of C4-compound 19 was increased
approximately ten fold to 9.6 from the value of 8.7 found for C3-
molecule 18 (entry 4). Conversely, the pIC50 and pA2 values of
20, the C5-homolog, decreased considerably to 7.5 and 8.0, respec-
tively (entry 5). As a consequence, the optimal chain length was
identiﬁed as being four carbon atoms, with the pA2 value (9.6) of
compound 19 being close to that of clobenpropit (10.0) (entry 6).
The inﬂuence of substituents at the 4-position of the phenyl
ring of 19 was further examined (Table 3). The strong electronwithdrawing triﬂuoromethyl group is employed frequently in the
contemporary drug development process; however, triﬂuoro-
methyl compound 21 did not improve either the pIC50 or pA2 val-
ues (7.8 and 7.9) compared to those of 19 (entry 2). The pIC50 of 4-
cyanophenyl compound 22 increased to 8.7 compared to that of 19,
but its pA2 value was lower 8.7 (entry 3). Although some dibasic
H3R antagonists have been recently reported,22 dipiperidine com-
pound 23 showed considerably high antagonistic activity (entry
4, pIC50 = 8.2; pA2 = 8.7).
Furthermore, the pIC50 values of three amide analogs (24–26),
where the isothioureylene group was substituted by carbamoyl
group, decreased more than 10 fold compared to that of 19, indi-
cating the importance of the protonated cationic nitrogen of the
isothiourea moiety as a pharmacophore against H3R at physiolog-
ical pH (entries 5–7).
As the H3R exhibits the highest degree of homology with H4R
among all the HR subtypes, a recurring issue in the development
of H3R ligands is the achievement of selectivity for H3R over H4R.
Indeed, imidazole-containing H3R antagonists such as thio-
peramide and clobenpropit, also display considerable H4R afﬁnities
as an antagonist and a partial agonist, respectively. The ﬁve most
potent H3R antagonists 17–19, 22, and 23 identiﬁed in the present
study were selected, and their efﬁcacy and potency against the
hH4R were further examined using CHO cells that stably express
the receptor.20a The ﬁve compounds, which showed H3R antagonis-
tic activities at a concentration of 1–10 nM, interestingly exhibited
neither agonistic nor antagonistic activities toward hH4R, even at a
concentration of 1 lM, as shown in Figure 2A and B.20a Such high
H3R selectivities were also found for CEP-26401 and ABT-239,
which are being evaluated in clinical trials.
Microdialysis is widely used to measure the extracellular levels
of different substances in the brain, and is suitable for the determi-
nation of neurotransmitter dynamics in vivo.18c,23 As a positive
control, we conﬁrmed clobenpropit signiﬁcantly increased hista-
mine release in the hypothalamus using this method (Fig. 3). The
pharmacological activities of the ﬁve homologs, 12, 17–20, which
contained the different methylene-spacers (n = 1–5), were tested
using this method in order to examine their effects on the release
of histamine in the rat hypothalamus (Table 4 and Fig. 3). Perfusion
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Figure 2. Functional (A) and antagonistic (B) activities of the piperidine derivatives
toward hH4R. CHO cells expressing hH4R were stimulated with forskolin (A) or
forskolin and histamine (B) in the presence of increasing concentrations of the
ligands. For comparison, the effects of H4 agonist histamine, partial agonist
clobenpropit and antagonist JNJ7777120 are illustrated in the graphs. TR-FRET
signal at 665 nm is inversely related to the intracellular cAMP concentration. Points
and bars represent the means ± SEM of two independent experiments.
Figure 3. Effects of 12, 17, 18, 19, and 20 on in vivo histamine release in rat
hypothalamus as measured by microdialysis. The compound (10 lM) was infused
into the hypothalamus via the microdialysis probe. The average value in the ﬁrst
three samples was taken as basal release. Results are expressed as percentages of
basal release and means ± SEM. The data were analyzed for signiﬁcant differences
using an analysis of variance (ANOVA), followed by post hoc Dunnet multiple
comparison tests. ⁄P < 0.05 versus basal release.
Table 4
In vivo rat brain microdialysis data for isothiourea homologs
N (CH2)3 S NH
(CH2)n
NH
Cl
Entry Compd no. n Histamine releasea (%)
1 12 1 134.4 ± 4.4
2 17 (OUP-181) 2 145.8 ± 3.3
3 18 3 102.2 ± 2.1
4 19 (OUP-186) 4 101.2 ± 1.4
5 20 5 90.5 ± 2.6
6 Clobenpropit 145.6 ± 6.7
a % Of basal histamine release.
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cantly increased histamine release to approximately 130–140%
that of the basal level (Table 4, entry 1), with 10 lM C2-spacercompound 17 further increasing the release to approximately
140–150% of the basal level (entry 2). As the three piperidine
homologs, 18–20 with C3–C5 chains, gave higher pIC50 (7.5–8.2)
and pA2 (8.0–9.6) values, we expected high levels of histamine re-
lease to be induced by these compounds in the in vivo experi-
ments. However, surprisingly, the rat brain microdialysis tests
revealed that they were completely inactive (Table 4, entries 3–
5; Fig. 3). These results suggest that 18–20 were inactive as H3R
antagonists in rats, but potent in humans. The pharmacology of
H3R ligands is known to be species-dependent, with some com-
pounds showing distinct afﬁnity proﬁles. For instance, imoproxifan
(Fig. 1) is an inverse agonist toward rH3R, but conversely, a full
agonist toward hH3R. However, to our knowledge, results suggest-
ing such a striking difference between these two species have not
been reported thus far.
In view of the fact that drug development for many human dis-
eases relies upon rodent-based models, it would be highly signiﬁ-
cant to elucidate the differences in the molecular mechanisms
through which C4-compound 19 (OUP-186) acts on hH3R, and C2-
homolog 17 (OUP-181) acts on rH3R. Hence, complex models of
19 in hH3R and 17 in rH3R were constructed by homology model-
ing based on a X-ray structure of hH1R TM domain; the sequence of
this H1R structure was most homologous to those of H3Rs in all of
GPCR X-ray structures analyzed to date (see Supplementary data,
Section 3).24 Among the amino acids that showed variation be-
tween the two species, only Thr119/Ala119 and Ala122/Val122
were found to be situated in the inner site of the TM region. This
site was located on the 3rd helix (TM3), consisting of the antago-
nist-binding site with the 5th and 6th helixes (TM5 and TM6). As
shown in Figure 4A, three hydrophilic interactions were observed
in the 19–hH3R model: (i) a hydrogen bond and electrostatic inter-
action between the piperidine group of 19 and the Asp114 side-
chain, (ii) a hydrogen bond and electrostatic interaction between
the > C ¼ NHþ2 group of 19 and the sidechains of Glu206 and
Thr119, and (iii) a p–H interaction between the >NH group of 19
and the indole ring of Trp371. The two hydrophobic moieties of
19 (propyl piperidine and chlorophenylbutyl) interacted with
two hydrophobic regions of hH3R, which included Leu111,
Tyr115, Tyr374, Phe398, Leu401 and Ala122, Ile125, Pro210,
Phe367, Trp371, respectively. The hydrogen bond between the
sidechains of Thr119 and Glu206 was retained in the complex
model (to aid understanding of the molecular interaction between
H3R and the antagonists, see Fig. S5 in the Supplementary data,
Section 3.4).20a We postulated that the position of 19 would be
ﬁxed by hydrogen bonds and electrostatic interactions, and that
its long, narrow shape could ﬁt tightly into the cavity of hH3R
due to hydrophobic interactions.
Similar interactions were also observed in the 17–rH3R model,
as shown in Figure 4B. Three hydrophilic interactions were ob-
served: (i) a hydrogen bond and electrostatic interaction between
the piperidine group of 17 and the Asp114 sidechain, (ii) a hydro-
gen bond and electrostatic interaction between the > C ¼ NHþ2
group of 17 and the sidechain of Glu206, and (iii) a hydrogen bond
between the >NH group of 17 and the Thr375 sidechain. In addi-
tion, a p–H interaction was shown between the benzene ring of
17 and the alkyl hydrogen atoms of the Val122 sidechain and
Phe207 mainchain. The maximum interatomic distance between
nonhydrogen atoms of 17 in rH3R was shorter (17.4 Å) than that
of 19 in hH3R (19.4 Å).
The two hydrophobic moieties of 17 (propyl piperidine and
chlorophenethyl) respectively interacted with two hydrophobic
regions, containing Leu111, Tyr115, Met378, Tyr394, and
Phe398; and Val122, Pro210, Phe367, Trp371, and Leu401. Be-
cause 17 has a more compact structure than 19, it could bind to
the shorter cavity of rH3R, ﬁlling up by the sidechain of Val122.
The side chain of Glu206 in the rH3R model would be ﬂexible
Figure 4. Predicted molecular structures of antagonists in hH3R and rH3R TM models. Molecular structures of the 19–hH3R and 17–rH3R complex models are shown in (A)
and (B), respectively. Compounds 19 and 17 are shown as the light-blue ball and stick model, with the neighboring residues of the receptors also indicated. The mainchains of
TM3, TM5, TM6, and TM7 are represented by the white alpha-trace. Hydrogen bonds and p–H interactions between receptors and ligands are shown as blue and purple
dotted lines, respectively. Oxygen, nitrogen, sulfur, and chlorine atoms are shown in red, blue, yellow, and purple, respectively. Hydrogen atoms are only shown in the
sidechains of Ala122/Val122 to show the structural volume of these residues.
S. Harusawa et al. / Bioorg. Med. Chem. Lett. 23 (2013) 6415–6420 6419without the hydrogen bond to residue 119, and it was seen that
17 was ﬁxed to the site slightly close to the cavity entrance, com-
pared to the position of 19 in the hH3R model. This effect seemed
to be related to the stability of 17 in the rH3R model. The com-
pound 17 in the hH3R was also simulated, and it was stabilized
in the similar position of 17 in the rH3R (see Fig. S4 in the Supple-
mentary data, Section 3.3).20a We attempted to construct the
complex of 19 within rH3R, but failed to produce a stable model,
considering with theoretical potential energy of the whole molec-
ular system, because of the van der Waals repulsion between
chlorophenylbutyl group of 19 and Val122 side-chain. From these
ﬁndings, it is suggested that the Ala122/Val122 mutation would
be especially important in the binding selectivity of 19 and its
homologs to hH3R and rH3R.
Feng et al. recently reported the difference between two bind-
ing modes of clobenpropit to hH4R using the same template struc-
ture of hH1R as used in the present study. In addition, they
simulated one binding mode of hH3R.25 In that report, the antago-
nist was shown to be in the opposite direction to that reported
here, with the > C ¼ NHþ2 group and imidazole ring of clobenpropit
interacting with the Asp114 and Glu206 of hH3R, respectively. We
attempted to produce a model with these same interactions being
involved in the binding of 17 and 19 to hH3R and rH3R, but a plau-
sible molecular mechanism could not be identiﬁed. Furthermore, a
slight rotation of TM5 was found in the 17–rH3R model compared
to the rH3R model without the ligand (see Supplementary data,
Section 3), because of the lack of a hydrogen bond between residue
119 and Glu206. This molecular effect may be related to the differ-
ence in antagonism between hH3R and rH3R; however, this could
not be completely elucidated without considering the effect of
interaction with the G-protein of each species on the process of
receptor activation.
In summary, seventeen S-alkyl-N-alkylisothioureas and amide
derivatives containing various cyclic amines were newly synthe-
sized. From among these molecules, piperidine compounds 18,19 (OUP-186), 22, and 23 were identiﬁed as being the most potent
and selective hH3R antagonists; however, they were seen to be
inactive against hH4R. In in vivo rat microdialysis experiments,
although C2-homolog 17 (OUP-181) increased histamine release
in the brain of rats, C3–C5-compounds 18–20 were inactive. The
molecular modeling study using molecules 17 and 19 clariﬁed
some structural differences between the ligand-binding sites in
hH3R and rH3R, and even emphasized the importance of the
Ala122/Val122 mutation.
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